Buy article

Volume: 0 - Issue: 0

First page: 0 - Last page: 0

K. Berbalk - N.J. Campion - T.J. Bartosik - L. Liu - M. Pan - C. Morgenstern - V. Stanek - A. Tu - S. Stoshikj - J. Eckl-Dorna - S. Schneider

DOI: 10.4193/Rhin25.523

BACKGROUND: Dupilumab has demonstrated efficacy in Chronic Rhinosinusitis with Nasal Polyps. While its impact on sinonasal and asthma symptoms is well established, less is known about its effects on the demand for concomitant medications in long-term routine care.
METHODOLOGY: This retrospective longitudinal real-world study included 224 patients diagnosed with Chronic Rhinosinusitis with Nasal Polyps and treated with Dupilumab at a tertiary centre between 2019 and 2025, with a maximum follow-up of up to 4.5 years. At each visit, use of nasal sprays, asthma drugs, and other disease-related drugs was recorded. Linear mixed-effects models were fitted to assess longitudinal changes.
RESULTS: At baseline, patients reported a mean of 1.6 concomitant medications, most commonly INCS and inhaled asthma drugs. The total number of concomitant medications, the number of nasal sprays, asthma medications, and other disease-related drugs decreased significantly over time. Parallel improvements were observed in patient-reported outcome measures (SNOT-22, TNSS, ACT, miniAQLQ).
CONCLUSIONS: In this real-world cohort, Dupilumab treatment led to a sustained overall reduction in concomitant medication use, thereby lowering pharmacological burden while improving disease control.

Rhinology 0 - 0: 0-0, 0000